F. Hermitte

发表

How basal are triple‐negative breast cancers?

Daniel Birnbaum, Pascal Finetti, François Bertucci, 2008, International journal of cancer.

Prognostic and predictive value of the Immunoscore in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France PRODIGE-GERCOR cohort study.

P. Laurent-Puig, J. Galon, A. Duval, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

Identification and validation of an ERBB2 gene expression signature in breast cancers

Daniel Birnbaum, Pascal Finetti, François Bertucci, 2004, Oncogene.

Prognostic utility of immune markers and validation of Immunoscore in stage III colon carcinoma patients treated with adjuvant FOLFOX in a phase III trial (NCCTG N0147; Alliance).

D. Sargent, J. Galon, A. Shields, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Detection of the JAK2V617F mutation with the Ipsogen MutaScreen kit: absence of JAK2V617F does not mean absence of myeloproliferative neoplasm.

F. Hermitte, H. Peyro-saint-paul, 2010, Blood.

Immunoscore to provide prognostic information in low- (T1-3N1) and high-risk (T4 or N2) subsets of stage III colon carcinoma patients treated with adjuvant FOLFOX in a phase III trial (NCCTG N0147; Alliance).

D. Sargent, A. Benson, J. Galon, 2018 .

Association of immune markers and Immunoscore with survival of stage III colon carcinoma (CC) patients (pts) treated with adjuvant FOLFOX: NCCTG N0147 (Alliance).

D. Sargent, A. Benson, J. Galon, 2017 .

Real-time quantitative PCR (RQ-PCR) detection of minimal residual disease (MRD) by optimized WT1 assay to enhance risk stratification in acute myeloid leukemia (AML): A European leukemia net study [Abstract]

R. Hills, S. Schnittger, C. Preudhomme, 2007 .

Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study.

V. V. D. van der Velden, R. Hills, S. Schnittger, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Analytical validation of the Immunoscore and its associated prognostic value in patients with colon cancer

J. Galon, F. Hermitte, A. Kirilovsky, 2020, Journal for immunotherapy of cancer.

Colorectal cancer: A paradigmatic model for cancer immunology and immunotherapy.

Marieke E. Ijsselsteijn, R. Sanz-Pamplona, F. Hermitte, 2019, Molecular aspects of medicine.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

Charles J. Vaske, Rohan N. Borkar, Brian D. Kelly, 2016, Journal of Immunotherapy for Cancer.

A diagnostic biochip for the comprehensive analysis of MLL translocations in acute leukemia

J. Cayuela, F. Hermitte, V. Fert, 2004, Leukemia.

Development of a biochip‐based assay integrated in a global strategy for identification of fusion transcripts in acute myeloid leukemia: a work flow for acute myeloid leukemia diagnosis

C. Formisano-Tréziny, F. Hermitte, C. Picard, 2009, International journal of laboratory hematology.

EQUAL-quant: an international external quality assessment scheme for real-time PCR.

Michael Neumaier, Mario Pazzagli, Ettore Marubini, 2006, Clinical chemistry.

Contribution of Immunoscore and Molecular Features to Survival Prediction in Stage III Colon Cancer

A. Benson, J. Galon, R. Goldberg, 2020, JNCI cancer spectrum.

Safety, Antitumor Activity, and T-cell Responses in a Dose-Ranging Phase I Trial of the Oncolytic Peptide LTX-315 in Patients with Solid Tumors

J. Galon, J. Spicer, F. Hermitte, 2021, Clinical Cancer Research.

Comparison of Immune Response Assessment in Colon Cancer by Immunoscore (Automated Digital Pathology) and Pathologist Visual Scoring

J. Galon, F. Hermitte, A. Kassambara, 2022, Cancers.

Prognostic and predictive value of the Immunoscore in stage III colon cancer patients treated with mFOLFOX6 (three versus six months) in the prospective IDEA France cohort study (PRODIGE-GERCOR).

P. Laurent-Puig, J. Galon, A. Duval, 2020 .

Evolution of Mutational Landscape and Tumor Immune-Microenvironment in Liver Oligo-Metastatic Colorectal Cancer

F. Izzo, P. Delrio, G. Botti, 2020, Cancers.

Corrigendum to 'Prognostic and predictive value of the Immunoscore in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France PRODIGE-GERCOR cohort study': Annals of Oncology 2020; Volume 31: 921-929.

P. Laurent-Puig, J. Galon, A. Duval, 2020, Annals of Oncology.

1 Gene expression profile predicts outcome after anthracycline-based adjuvant chemotherapy in early breast cancer

F. Bertucci, D. Birnbaum, P. Finetti, 2017 .

Gene expression profile predicts outcome after anthracycline-based adjuvant chemotherapy in early breast cancer

F. Bertucci, D. Birnbaum, P. Finetti, 2011, Breast Cancer Research and Treatment.

Genetic trajectory and immune microenvironment of lung-specific oligometastatic colorectal cancer

G. Botti, G. Liguori, M. Caraglia, 2020, Cell Death & Disease.

MedicalAffairsDepartment,IpsogenSA,LuminyBiotechEntreprises,Marseille,France ResearchandDevelopmentDepartment,IpsogenSA,LuminyBiotechEntreprises,Marseille,France

F. Hermitte, 2010 .

Validation of the Immunoscore prognostic value in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France cohort study (PRODIGE-GERCOR).

P. Laurent-Puig, J. Galon, A. Duval, 2019, Journal of Clinical Oncology.

Biomarkers immune monitoring technology primer: Immunoscore® Colon

F. Hermitte, Fabienne Hermitte, 2016, Journal of Immunotherapy for Cancer.

Immunoscore clinical utility to identify good prognostic colon cancer stage II patients with high-risk clinico-pathological features for whom adjuvant treatment may be avoided.

F. Marincola, P. Ascierto, I. Nagtegaal, 2019, Journal of Clinical Oncology.

Significant differences in outcome between Immunoscore categories in stage I colon cancer patients.

F. Marincola, P. Ascierto, I. Nagtegaal, 2019, Annals of Oncology.

MSI status plus immunoscore to select metastatic colorectal cancer patients for immunotherapies

F. Marincola, P. Ascierto, I. Nagtegaal, 2018, Annals of Oncology.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

Charles J. Vaske, Rohan N. Borkar, David M. Schauder, 2016, Journal for ImmunoTherapy of Cancer.